These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 23933320)

  • 1. Senescence marker protein 30 inhibits angiotensin II-induced cardiac hypertrophy and diastolic dysfunction.
    Misaka T; Suzuki S; Miyata M; Kobayashi A; Ishigami A; Shishido T; Saitoh S; Kubota I; Takeishi Y
    Biochem Biophys Res Commun; 2013 Sep; 439(1):142-7. PubMed ID: 23933320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of senescence marker protein 30 exacerbates angiotensin II-induced cardiac remodelling.
    Misaka T; Suzuki S; Miyata M; Kobayashi A; Shishido T; Ishigami A; Saitoh S; Hirose M; Kubota I; Takeishi Y
    Cardiovasc Res; 2013 Aug; 99(3):461-70. PubMed ID: 23723062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Senescence marker protein 30 has a cardio-protective role in doxorubicin-induced cardiac dysfunction.
    Miyata M; Suzuki S; Misaka T; Shishido T; Saitoh S; Ishigami A; Kubota I; Takeishi Y
    PLoS One; 2013; 8(12):e79093. PubMed ID: 24391705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac-specific overexpression of diacylglycerol kinase zeta prevents Gq protein-coupled receptor agonist-induced cardiac hypertrophy in transgenic mice.
    Arimoto T; Takeishi Y; Takahashi H; Shishido T; Niizeki T; Koyama Y; Shiga R; Nozaki N; Nakajima O; Nishimaru K; Abe J; Endoh M; Walsh RA; Goto K; Kubota I
    Circulation; 2006 Jan; 113(1):60-6. PubMed ID: 16380548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions.
    Wang H; Shimosawa T; Matsui H; Kaneko T; Ogura S; Uetake Y; Takenaka K; Yatomi Y; Fujita T
    J Hypertens; 2008 Jul; 26(7):1453-62. PubMed ID: 18551023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
    Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
    Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calsarcin-1 protects against angiotensin-II induced cardiac hypertrophy.
    Frank D; Kuhn C; van Eickels M; Gehring D; Hanselmann C; Lippl S; Will R; Katus HA; Frey N
    Circulation; 2007 Nov; 116(22):2587-96. PubMed ID: 18025526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy.
    Zhai P; Galeotti J; Liu J; Holle E; Yu X; Wagner T; Sadoshima J
    Circ Res; 2006 Sep; 99(5):528-36. PubMed ID: 16902180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related oxidant stress with senescence marker protein-30 deficiency plays a pivotal role in coronary artery spasm.
    Hoshino Y; Yamada S; Saitoh S; Machii H; Mizukami H; Miyata M; Misaka T; Ishigami A; Takeishi Y
    Coron Artery Dis; 2013 Mar; 24(2):110-8. PubMed ID: 23291859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension.
    Letavernier E; Perez J; Bellocq A; Mesnard L; de Castro Keller A; Haymann JP; Baud L
    Circ Res; 2008 Mar; 102(6):720-8. PubMed ID: 18258859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
    Westermann D; Becher PM; Lindner D; Savvatis K; Xia Y; Fröhlich M; Hoffmann S; Schultheiss HP; Tschöpe C
    Basic Res Cardiol; 2012 Nov; 107(6):308. PubMed ID: 23117837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoprotective roles of senescence marker protein 30 against intracellular calcium elevation and oxidative stress.
    Son TG; Kim SJ; Kim K; Kim MS; Chung HY; Lee J
    Arch Pharm Res; 2008 Jul; 31(7):872-7. PubMed ID: 18704329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated intracardiac angiotensin II leads to cardiac hypertrophy and mechanical dysfunction in normotensive mice.
    Huggins CE; Domenighetti AA; Pedrazzini T; Pepe S; Delbridge LM
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):186-90. PubMed ID: 14608525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpressed connective tissue growth factor in cardiomyocytes attenuates left ventricular remodeling induced by angiotensin II perfusion.
    Zhang Y; Yan H; Guang GC; Deng ZR
    Clin Exp Hypertens; 2017; 39(2):168-174. PubMed ID: 28287886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
    Izumiya Y; Kim S; Izumi Y; Yoshida K; Yoshiyama M; Matsuzawa A; Ichijo H; Iwao H
    Circ Res; 2003 Oct; 93(9):874-83. PubMed ID: 14551246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension.
    Tsushima K; Osawa T; Yanai H; Nakajima A; Takaoka A; Manabe I; Ohba Y; Imai Y; Taniguchi T; Nagai R
    FASEB J; 2011 May; 25(5):1531-43. PubMed ID: 21266535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.
    Yamazaki T; Yamashita N; Izumi Y; Nakamura Y; Shiota M; Hanatani A; Shimada K; Muro T; Iwao H; Yoshiyama M
    Hypertens Res; 2012 Jan; 35(1):34-40. PubMed ID: 21866107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy-mediated degradation is necessary for regression of cardiac hypertrophy during ventricular unloading.
    Oyabu J; Yamaguchi O; Hikoso S; Takeda T; Oka T; Murakawa T; Yasui H; Ueda H; Nakayama H; Taneike M; Omiya S; Shah AM; Nishida K; Otsu K
    Biochem Biophys Res Commun; 2013 Nov; 441(4):787-92. PubMed ID: 24211573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding.
    Kee HJ; Sohn IS; Nam KI; Park JE; Qian YR; Yin Z; Ahn Y; Jeong MH; Bang YJ; Kim N; Kim JK; Kim KK; Epstein JA; Kook H
    Circulation; 2006 Jan; 113(1):51-9. PubMed ID: 16380549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac-specific Traf2 overexpression enhances cardiac hypertrophy through activating AKT/GSK3β signaling.
    Huang Y; Wu D; Zhang X; Jiang M; Hu C; Lin J; Tang J; Wu L
    Gene; 2014 Feb; 536(2):225-31. PubMed ID: 24378234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.